<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02112500</url>
  </required_header>
  <id_info>
    <org_study_id>STELLAR-Pilot</org_study_id>
    <nct_id>NCT02112500</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cell in Patients With Acute Severe Respiratory Failure</brief_title>
  <acronym>STELLAR</acronym>
  <official_title>A Pilot Study for the Efficacy and Safety of Mesenchymal Stem Cell in Acute Severe Respiratory Failure.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although the advent of advanced medical support for respiratory failure, the mortality rate
      of acute severe respiratory failure is still high and the life quality is frequently
      compromised from pulmonary fibrosis.

      The investigators hypothesize that the treatment using mesenchymal stem cell can be
      beneficial in patients with respiratory failure. The present study is a pilot study
      evaluating the efficacy and safety of mesenchymal stem cell treatment in patients with
      respiratory failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although the advent of advanced medical support for respiratory failure, the mortality rate
      of acute severe respiratory failure is still reported to be more than 40%. The respiratory
      distress syndrome may develop in all ages resulting in progressive pulmonary fibrosis. A
      number of survivors from respiratory failure suffer from the sequelas of pulmonary fibrosis.

      However, the treatments of respiratory failure are limited to the correction of baseline
      disease, cardiopulmonary support, and conservative management to minimize the lung injury.
      There has not been any effective and specific treatment for respirator distress nor medicine
      to reduce mortality.

      There have been reports of mesenchymal stem cell experimental animals with chronic
      obstructive pulmonary disease, interstitial lung disease, and sepsis. In addition, the
      mesenchymal stem cell treatment showed beneficial effect in bleomycin endotoxin induced lung
      injury.

      Authors hypothesize that the mesenchymal stem cell treatment in patients with respiratory
      failure will show efficacy. We would conduct the present pilot study to evaluate the efficacy
      and safety in patients with respiratory failure and intend to suggest an additional
      alternative treatment option for those without additional treatment option.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxygen index at 3 days after mesenchymal stem cell infusion</measure>
    <time_frame>3 days after mesenchymal stem cell infusion</time_frame>
    <description>Oxygen index at 3 days after mesenchymal stem cell infusion. Oxygen index is calculated as follows; ((FiO2) x (Mean airway pressure)) / (PaO2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lung mechanics</measure>
    <time_frame>at 3, 14, and 28 days after mesenchymal stem cell infusion</time_frame>
    <description>Lung mechanics includes arterial oxygen saturation, tidal volume, minute ventilation, and ratio of PaO2/FiO2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic parameters</measure>
    <time_frame>at 3, 14, and 28 days after mesenchymal stem cell infusion</time_frame>
    <description>Systolic, diastolic, and mean arterial blood pressure Amount of required vasopressor Heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>at 14 and 28 days after mesenchymal stem cell infusion</time_frame>
    <description>Death from any cause at 14 and 28 days after mesenchymal stem cell infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma cytokines</measure>
    <time_frame>at 3, 14, and 28 days after mesenchymal stem cell infusion</time_frame>
    <description>Interleukin (IL)-1, IL-6, IL-8, and IL-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers for inflammation and infection</measure>
    <time_frame>at 3, 14, and 28 days after mesenchymal stem cell infusion</time_frame>
    <description>Lactate, DIC score, SOFA score, C-reactive protein, and procalcitonin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator weaning parameters</measure>
    <time_frame>at 3, 14, and 28 days after mesenchymal stem cell infusion</time_frame>
    <description>Failure of ventilator weaning, weaning time, ventilation time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU and hospital stay</measure>
    <time_frame>at 28 days after mesenchymal stem cell infusion</time_frame>
    <description>Total duration of ICU stay and hospital stay</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Respiratory Distress Syndrome, Adult</condition>
  <arm_group>
    <arm_group_label>Mesenchymal Stem Cell Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mesenchymal stem cells cultured and extracted from bone marrow of enrolled patients are infused.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal Stem Cell</intervention_name>
    <description>Mesenchymal stem cells will be intravenously infused. Mesenchymal stem cells will be cultured and extracted from the bone marrow of the patients.</description>
    <arm_group_label>Mesenchymal Stem Cell Infusion</arm_group_label>
    <other_name>Lungcellgram</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ventilator care from respiratory failure

          -  Ventilator care for 7 or more days

          -  at least one of the followings

               1. PaO2/FiO2 = 200 or less when PEEP 5 cmH2O or more.

               2. PaCO2 = 50 mmHg or more when plateau pressure of 30 cmH2O or more.

               3. pH = 7.25 or less when plateau pressure of 30 cmH2O or more.

               4. No other treatment option except for lung transplantation and not candidate for
                  recipient (organ failure, comorbid infection, economy,...)

               5. Ventilatory care with weaning failure 3 times or more

               6. Ventilator care requiring 7 days or more from the first self respiration to
                  weaning of ventilator.

                    -  PEEP, positive endexpiratory pressure

        Exclusion Criteria:

          -  Severe aplastic anemia

          -  Malignant hematologic disorder or history of stem cell treatment.

          -  Currently uncontrolled malignancy or history of solid cancer within 2 years

          -  HIV Infection

          -  Expected life &lt; 3 months from other cause than the respiratory failure

          -  Pregnancy or breast feeding

          -  Expected hypersensitivity for study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang Bum Hong, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sang Bum Hong, MD</last_name>
    <phone>+82-10-6824-9767</phone>
    <email>hongsangbum@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dong Hyun Lee, MD</last_name>
    <phone>+82-10-6476-0706</phone>
    <email>rvotvt@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Bum Hong, MD</last_name>
      <phone>+82-10-6824-9767</phone>
      <email>hongsangbum@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sang Bum Hong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Calfee CS, Matthay MA. Nonventilatory treatments for acute lung injury and ARDS. Chest. 2007 Mar;131(3):913-920. doi: 10.1378/chest.06-1743. Review.</citation>
    <PMID>17356114</PMID>
  </reference>
  <reference>
    <citation>Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, Hudson LD. Incidence and outcomes of acute lung injury. N Engl J Med. 2005 Oct 20;353(16):1685-93.</citation>
    <PMID>16236739</PMID>
  </reference>
  <reference>
    <citation>D'Agostino B, Sullo N, Siniscalco D, De Angelis A, Rossi F. Mesenchymal stem cell therapy for the treatment of chronic obstructive pulmonary disease. Expert Opin Biol Ther. 2010 May;10(5):681-7. doi: 10.1517/14712591003610614. Review.</citation>
    <PMID>20384521</PMID>
  </reference>
  <reference>
    <citation>Lee JW, Gupta N, Serikov V, Matthay MA. Potential application of mesenchymal stem cells in acute lung injury. Expert Opin Biol Ther. 2009 Oct;9(10):1259-70. doi: 10.1517/14712590903213651. Review.</citation>
    <PMID>19691441</PMID>
  </reference>
  <reference>
    <citation>Stagg J. Immune regulation by mesenchymal stem cells: two sides to the coin. Tissue Antigens. 2007 Jan;69(1):1-9. Review.</citation>
    <PMID>17212702</PMID>
  </reference>
  <reference>
    <citation>Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol. 2007 Aug 1;179(3):1855-63.</citation>
    <PMID>17641052</PMID>
  </reference>
  <reference>
    <citation>Lee JW, Fang X, Gupta N, Serikov V, Matthay MA. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16357-62. doi: 10.1073/pnas.0907996106. Epub 2009 Aug 31.</citation>
    <PMID>19721001</PMID>
  </reference>
  <reference>
    <citation>Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, Phinney DG. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):11002-7. Epub 2007 Jun 14.</citation>
    <PMID>17569781</PMID>
  </reference>
  <reference>
    <citation>Moodley Y, Atienza D, Manuelpillai U, Samuel CS, Tchongue J, Ilancheran S, Boyd R, Trounson A. Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury. Am J Pathol. 2009 Jul;175(1):303-13. doi: 10.2353/ajpath.2009.080629. Epub 2009 Jun 4.</citation>
    <PMID>19497992</PMID>
  </reference>
  <reference>
    <citation>Rojas M, Xu J, Woods CR, Mora AL, Spears W, Roman J, Brigham KL. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol. 2005 Aug;33(2):145-52. Epub 2005 May 12.</citation>
    <PMID>15891110</PMID>
  </reference>
  <reference>
    <citation>Zhen G, Liu H, Gu N, Zhang H, Xu Y, Zhang Z. Mesenchymal stem cells transplantation protects against rat pulmonary emphysema. Front Biosci. 2008 May 1;13:3415-22.</citation>
    <PMID>18508443</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2014</study_first_submitted>
  <study_first_submitted_qc>April 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2014</study_first_posted>
  <last_update_submitted>January 8, 2016</last_update_submitted>
  <last_update_submitted_qc>January 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Sang Bum Hong</investigator_full_name>
    <investigator_title>MD, Professor of Ulsan University College of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

